Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.
The intraperitoneal delivery of cisplatin or carboplatin in the management of ovarian cancer is based on a sound pharmacokinetic rationale. Objective responses, including surgically documented complete responses, have been observed in patients with ovarian cancer who have previously responded to systemic platinum-based therapy. A precise role for intraperitoneal cisplatin or carboplatin in the management of ovarian cancer remains to be defined.